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Huo et al. screen in vivo for genes that
promote mammary tumorigenesis in
primary MMTV-ErbB2 mammary tissue.
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GTF2IRD1, which promotes mammary
cancer through induction of TGFbR2 and
downregulation of BMPR1b. GTF2IRD1
expression in human breast cancers
correlates with high tumor grades and
poor prognosis.
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The broad implementation of precision medicine in
cancer is impeded by the lack of a complete inven-
tory of the genes involved in tumorigenesis. We per-
formed in vivo screening of 1,000 genes that are
associated with signaling for positive roles in breast
cancer, using lentiviral expression vectors in primary
MMTV-ErbB2 mammary tissue. Gain of function
of five genes, including RET, GTF2IRD1, ADORA1,
LARS2, and DPP8, significantly promoted mammary
tumor growth.We further studied one tumor-promot-
ing gene, the transcription factor GTF2IRD1. The
mis-regulation of genes downstream of GTF2IRD1,
including TbR2 and BMPR1b, also individually pro-
moted mammary cancer development, and silencing
of TbR2 suppressed GTF2IRD1-driven tumor promo-
tion. In addition, GTF2IRD1 is highly expressed in
human breast tumors, correlating with high tumor
grades and poor prognosis. Our in vivo approach is
readily expandable to whole-genome annotation of
tumor-promoting genes.INTRODUCTION
Breast cancer is a global health problem, whichwill likely grow as
the at-risk population ages. Recent years have witnessed the
development of precision medicine as a therapeutic strategy
(Meric-Bernstam et al., 2013). Precision medicine formulates
treatments based on the genetic changes in a specific cancer,
and it can dramatically enhance the response rate over conven-
tional treatments. However, the broad application of precision
medicine requires full knowledge of the primary driver genes
and their functions, plus multiple other genes that can potentiate
or accelerate tumorigenesis.
Cancer genes can be identified through unbiased forward ge-
netics approaches, and small hairpin RNA (shRNA)-based gene
libraries frequently have been used to screen for cancer sup-
pressor genes in multiple systems (Wolf et al., 2014; Zender
et al., 2008). Recently, in vivo screening using primary cells ofCel
This is an open access article under the CC BY-Norigin (as opposed to cell lines) has shown great potential for
the discovery of tumor suppressor genes under physiological
conditions (Bric et al., 2009; Schramek et al., 2014; Beronja
et al., 2013), although this approach has not yet been applied
to breast cancer. Gene upregulation, through epigenetic and
other mechanisms, is an important additional driver of many as-
pects of cancer (Ding et al., 2013), but gain-of-function screening
has not yet been widely implemented in vivo. In this study, we
used mammary glands as an example, in which high-throughput
library screening has not previously been proven feasible, to
functionally identify tumor-promoting genes using a gain-of-
function approach in vivo.
RESULTS
Optimization of the Mammary Gland Regeneration
System to Identify Breast Tumor-Promoting Genes
In Vivo
Murine mammary stem cells can regenerate entire mammary
glands when transplanted into syngeneic recipients (Shackleton
et al., 2006; Stingl et al., 2006), which provides a facile approach
to interrogate gene function in the mammary gland under phys-
iological conditions and to identify novel cancer genes (Fig-
ure 1A). MMTV-ErbB2 transgenic mice were used as the
mammary stem cell donor in this study, because ErbB2 is a clin-
ically relevant oncogene in breast cancer (van de Vijver et al.,
1988). MMTV-ErbB2 transgenic mice consistently form mam-
mary tumors with a latency of 5 months (Siegel et al., 1999).
However, after transplantation into the cleared fat pads of
wild-type syngeneic recipient mice, MMTV-ErbB2 cells did not
form tumors for more than 9months. Therefore, we could screen
for genes that would significantly reduce tumor latency in this
mammary cell transplantation model.
We chose a cDNA lentiviral library over the more broadly used
small interfering RNA (siRNA) libraries because gain-of-function
drivers are more accessible to drug targeting than are loss-of-
function mutations (Wang et al., 2006). The library contains
1,000 genes that encode proteins involved in signaling path-
ways (Hopkins and Groom, 2002). All open reading frames
(ORFs) were constructed in a bicistronic lentiviral vector, in
which each ORF is tagged with red fluorescent protein (RFP)
and a puromycin resistance gene is expressed downstream ofl Reports 15, 2089–2096, June 7, 2016 ª 2016 The Author(s). 2089
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. An In Vivo Screening Identifies RET, DPP8, ADORA1, LARS2, and GTF2IRD1 as Breast Tumor-Promoting Genes
(A) Schematic view of the in vivo screening system. Mammary gland stem/progenitor cells were isolated from 6- to 8-week-old ErbB2 transgenic mice and
transduced with a lentiviral cDNA library. After transplantation into the cleared fat pads of syngeneic hosts, these cells regenerated mammary glands. Tumors
formed in 4/40 mice after 8 months. DNA was isolated from the tumors and the lentiviral genes identified by sequencing.
(B) RET, DPP8, ADORA1, LARS2, and GTF2IRD1 were identified from tumors in the regenerated mammary glands.
(C) Schematic of the validation process. Mammary gland stem/progenitor cells from MMTV-ErbB2 mice were transduced with individual candidate genes
expressed from lentiviruses.
(D) DPP8, ADORA1, LARS2, and GTF2IRD1 each drives tumor formation in mammary glands. The LARS2-driven tumors show an invasive papillary carcinoma
phenotype and the rest are invasive ductal carcinomas.
See also Figures S1 and S2 and Table S1.
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the ORFs to enable selection (Figures S1A and S1C). Two prob-
lems with using cDNA libraries are that, first, since lentivirus
packaging efficiency decreases dramatically as vector size in-
creases, geneswill not be represented equally; and second,mul-
tiple genes might function collaboratively in one cell to promote
tumorigenesis. Therefore, prior to packaging, we divided the
library into 12 sub-groups based on the sizes of the ORFs (Table
S1). An MOI of two was adopted as a compromise between the
availability of primary cells and the necessity for low virus copy
numbers in each cell (Figure S1B).
Identification of Breast Tumor-Promoting Genes
Primary mammary gland stem/progenitor cells isolated from
6- to 8-week-old MMTV-ErbB2 transgenic mice were trans-
duced with the lentiviral cDNA library. Cells were selected by pu-
romycin for 3 days to enrich for cells containing lentiviral vectors
(Figure S1C). Protein distribution, as detected by the in-frame
RFP fusion, showed distinct patterns in different cells (Fig-
ure S1D). These cells were transplanted into the cleared fat
pads of 40 syngeneic recipients.
One limitation intrinsic to this type of in vivo screen is the lack
of knowledge of the mammary cell of origin from which tumors
might arise, along with the heterogenous population of cells
being transduced, which makes any calculation of coverage
problematic. The potential range of coverage is 1.5 (if only
stem cells can generate tumors) to about 2,500 (if all cells can
generate tumors). However, since ErbB2+ tumors have luminal
characteristics, we speculated that the cell of origin might be a
luminal progenitor, which constitutes about 14% of total mam-
mary epithelium at 6–10 weeks of age, suggesting a maximum
coverage of 350 (Giraddi et al., 2015). Nonetheless, given the
uncertainty regarding the actual coverage achieved in vivo in
this screen, we cannot exclude the possibility that some genes
in the library were not queried for their involvement in tumor
promotion.
Importantly, the transplanted cells, which overexpressed
ErbB2, formed normal mammary ductal trees within 6 weeks.
After another 8 months latency, small tumors along the mam-
mary ducts were detected in 4/40 mice transplanted with cells
that had been infected with the lentiviral sublibraries (Fig-
ure 1B). No tumors were found at this time in ten control
mice transplanted with control MMTV-ErbB2 cells. We ex-
tracted genomic DNA from the tumors and identified indi-
vidual genes by sequencing across the integrated lentivirus.
The following five genes were identified: RET, GTF2IRD1,
ADORA1, LARS2, and DPP8. No tumor expressed multiple
lentiviral genes; but, one mouse had two tumors, each of
which expressed a different gene (Figure 1B). Among the
hits, RET is known to promote mammary tumorigenesis (Mul-
ligan, 2014) and served to validate our approach. The other
four genes had never been shown to function as breast cancer
genes.
One potential problem is that the integration of lentivirus might
activate an endogenous oncogene, or inactivate a tumor sup-
pressor to promote ErbB2-driven tumor formation. Therefore,
we next expressed the four candidates individually in mammary
cells from MMTV-ErbB2 transgenic mice (Figure 1C). Each of
the four genes promoted breast tumor formation. LARS2-over-expressing tumors were of the invasive papillary carcinoma
phenotype, while tumors with the other three genes, GFT2IRD1,
ADORA1, and DPP8, showed invasive ductal carcinoma pheno-
types (Figure 1D). These results demonstrated that all four genes
individually can promote tumor growth.
One interesting gene is general transcription factor 2I repeat
domain-containing protein 1 (GTF2IRD1, also called Ben). Hap-
loinsufficiency of GTF2IRD1 causes Williams-Beuren syndrome
(Franke et al., 1999; Tassabehji et al., 2005). Patients with this
syndrome suffer from a variety of symptoms, including hyper-
tension, diabetes, osteoporosis, and anxiety (Pober, 2010).
A detailed analysis of the tumors driven by GTF2IRD1 showed
that about 70% of the tumors were invasive ductal carcinomas
and the rest ranged from ductal hyperplasia to lobular carci-
noma to invasive papillary carcinoma (Figure S1E), which is
similar to the prevalence of histological subtypes in human
breast cancer (Viale, 2012). We next asked if GTF2IRD1 is ex-
pressed in human cancers. We analyzed existing databases
and found that GTF2IRD1 expression is significantly increased
not only in invasive breast ductal carcinoma but also in lung
and ovarian cancers (Figures S2A, S2C, and S2E) (Gaglio
et al., 1995; Selamat et al., 2012). High GTF2IRD1 correlates
to poor overall survival of patients with breast cancer, lung can-
cer, or ovarian cancer (Figures S2B, S2D, and S2F) (Gyo¨rffy
et al., 2010, 2012, 2013). These data suggest that GTF2IRD1
is a bona fide tumor-promoting gene relevant to human cancer.
Together, these experiments demonstrate the efficacy of gain-
of-function screens in the mammary gland system under phys-
iological conditions.
GTF2IRD1 Functions through Downstream Genes TbR2
and BMPR1b
We next sought to understand how GTF2IRD1 contributes to
breast cancer development. First, we asked if the lentivirus-
driven expression of GTF2IRD1 in the tumors was within a phys-
iologically relevant range, and we found a 2.5-fold increase
compared to that in normal mammary gland tissues (Figure 2A).
This is comparable to the observed increases in human invasive
breast cancers, which have an 1.8-fold increase in GTF2IRD1
mRNA compared to that in normal human mammary tissues
(Figure S2A).
We then examined downstream effectors of GTF2IRD1.
Several genome-wide studies have uncovered genes that
are regulated by GTF2IRD1 in mice, including TbR1, TbR2,
SMAD5,OPN, andBMPR1b (Chimge et al., 2008; Enkhmandakh
et al., 2009; Lazebnik et al., 2008). We initially tested these genes
using the untransformed human mammary gland cell line,
MCF10A. Overexpression of GTF2IRD1 in MCF10A cells caused
small but significant increases inOPN and TbR2 transcript levels
and decreased BMPR1b mRNA level, compared to the vector
control (Figure 2B). However, no significant changes were de-
tected for TbR1 and SMAD5. We also examined the protein
levels of OPN, TbR2, and BMPR1b by immunoblot, andwe found
qualitatively similar responses to the changes in mRNA (Figures
2C and 2D).
We next asked if related expression changes occur in mouse
breast tumors. TbR2 and bmpr1b expression were regulated
the same way as in MCF10A cells. However, OPN expressionCell Reports 15, 2089–2096, June 7, 2016 2091
Figure 2. GTF2IRD1 Regulates Expression
of OPN, TbR2, and BMPR1b in MCF10A
Cells and Breast Tumors
(A)GTF2IRD1 expression in tumors was increased
2.5-fold compared to normal mammary gland tis-
sues. Error bars represent mean ± SD (n = 4).
(B) Overexpression of GTF2IRD1 in MCF10A cells
increased OPN and TbR2 transcript levels and
decreased BMPR1B mRNA levels significantly
compared to the vector control, but had no effects
on SMAD5 and TbR1mRNA levels, as assayed by
qPCR (n = 3).
(C and D) Immunoblot analysis confirmed that
overexpression of GTF2IRD1 in MCF10A cells
upregulated OPN and TbR2 and downregulated
BMPR1b protein levels (C). Immunoblots were
quantified and results are summarized in (D) (n = 3).
(E) In tumors, GTF2IRD1 overexpression upregu-
lated TbR2 and downregulatedOPN and BMPR1b
levels significantly. Error bars represent mean ±
SEM (n = 3).
(F and G) Phospho-Smad2 levels were measured
in MCF10A cells by immunoblot (F). Protein levels
were quantified and results are summarized in (G).
Error bars represent mean ± SD; n = 3; p values
were calculated by a two-tailed paired Student’s
t test.was significantly decreased in tumors expressing GTF2IRD1
compared to the control tumors (Figure 2E). This opposite
behavior might reflect species differences or a difference
in the tumor environment or gene regulatory network, as
compared to a cell line in culture. The surprise was TbR2,
because it is widely known as a tumor suppressor gene (Guasch
et al., 2007; Novitskiy et al., 2011). Nonetheless, loss of TbR2
can increase breast tumor latency in a MMTV-Neu transgenic
mouse model (Novitskiy et al., 2014), suggesting that it may
have paradoxical effects in tumors as compared to normal
tissues.
TGF-b signals are transmitted via phosphorylation and
nuclear translocation of the Smad family members. To further
test if TbR2 is a downstream target of GTF2IRD1, we measured
phospho-Smad2 levels in MCF10A cells overexpressing
GTF2IRD1 or TbR2. Immunoblot analysis showed that phospho-
Smad2 levels were significantly higher in the cells expressing
GTF2IRD1, or TbR2, than in cells with the empty vector control2092 Cell Reports 15, 2089–2096, June 7, 2016(Figures 2F and 2G). These data demon-
strate GTF2IRD1 upregulates membrane
TbR2 levels, which mediate an elevated
TGF-b activity.
DoOPN, TbR2, andBMPR1b act down-
stream of the GTF2IRD1 gene to promote
breast cancer development? We asked
whether these genes promote tumori-
genic behavior in MCF10A cells in vitro
and in mouse mammary glands in vivo.
MCF10A stable cell lines were established
that express control vector or vectors
expressing GTF2IRD1, OPN, or TbR2, or
shRNA against BMPR1b. These cell lineswere then used to assess proliferation rates, soft agar colony
formation, and tumorsphere growth. Notably, GTF2IRD1 and
its downstream target genes all suppressed cell proliferation
compared to the control vector, for cells grown in 2D culture (Fig-
ureS3A). However, they all promotedcolony formation in soft agar
and tumorsphere formation under anchorage-independent
growth conditions (Figures S3B and S3C).
We also manipulated gene expression in mouse mam-
mary stem/progenitor cells to study their impact on mammary
cancer development in vivo. Lentiviruses to overexpress
GTF2IRD1,OPN, or TbR2 or shRNA against BMPR1bwas trans-
duced into mammary gland stem/progenitor cells isolated from
MMTV-ErbB2 transgenic mice. These cells were then trans-
planted into cleared fat pads of syngeneic recipients to regen-
erate mammary glands. Mice were palpated once a week to
detect breast tumors until tumors had formed in mice with the
control vector. GTF2IRD1, TbR2, and shRNA against BMPR1b
accelerated tumor incidence significantly compared to the
Figure 3. GTF2IRD1 Promotes Breast
Tumor Formation through Its Downstream
Genes TbR2 and BMPR1b
(A) GTF2IRD1 and TbR2 overexpression or
BMPR1b silencing each decreased tumor forma-
tion latency significantly compared to the vector
control. Tumor-free survival curves were gener-
ated using Prism software (version 6.0, GraphPad).
The p values were calculated for the experimental
groups compared to the vector control group.
(B) Histology shows that overexpression of
GTF2IRD1 or TbR2 or depletion of BMPR1b pro-
motes formation of invasive ductal carcinomas
and lung metastases in mice.
(C) GTF2IRD1 and its downstream effectors TbR2
and BMPR1B drive high-grade tumor develop-
ment.
(D) Depletion of TbR2 in GTF2IRD1-over-
expressing mammary gland stem/progenitor cells
significantly increased tumor latency compared to
overexpression of GTF2IRD1 alone.
See also Figure S3.control vector (Figure 3A). OPN had no significant effect. We
conclude that TbR2 and BMPR1b act in opposite ways down-
stream of GTF2IRD1 to promote breast tumor formation.
We next analyzed the histology of mouse breast tumors driven
by GTF2IRD1, TbR2, and shRNA against BMPR1b. The majority
of tumors were invasive ductal carcinomas with low levels of
ductal or lobular hyperplasia (Figures 3B and S3D). Quantitative
analysis showed that dysregulation of TbR2 or BMPR1b drove
high-grade tumor formation, which is consistent with the
GTF2IRD1 tumors (Figure 3C).Cell RTo determine whether the tumor-pro-
moting activity of GTF2IRD1 is dependent
on the dysregulation of these downstream
genes, we asked whether reversal of the
expression of one of the key downstream
genes, in combination with GTF2IRD1
overexpression, would impact tumor inci-
dence. Using shRNA, TbR2 expression
was silenced in ErbB2 mammary cells
that overexpressed GTF2IRD1, and the
cells were transplanted into recipient
mice. Tumor latency was significantly
increased when TbR2 expression was
suppressed, compared to GTF2IRD1
overexpression alone (Figure 3D).
The few tumors that arose from cells
expressing GTF2IRD1 and depleted of
TbR2 were similar histologically to those
expressing GTF2IRD1, with invasive
ductal carcinoma phenotypes. However,
all tumors showed apparent hemor-
rhaging, in contrast to those tumors that
expressed GTF2IRD1 alone (Figure S3E).
This observation is consistent with a
previous study showing that suppression
of TbR2 increases vasculogenesis andblood vessel leakage (Novitskiy et al., 2014). These data support
a molecular mechanism in which GTF2IRD1 induces TbR2,
which, together with reduced BMPR1b expression, promotes
mammary tumorigenesis.
GTF2IRD1 Is a Clinically Relevant Breast Tumor-
Promoting Gene
Finally, we asked what clinicopathologic traits GTF2IRD1
contributes to breast cancer in patients. We evaluated the
association between GTF2IRD1 protein levels and cancereports 15, 2089–2096, June 7, 2016 2093
Table 1. Correlation of GTF2IRD1 Protein Expression with





Tumor size (cm) %2 133 72.5 27.0 0.14
>2 69 78.6 29.3
Tumor grade I 36 69.6 26.1 0.04
II 73 70.3 30.3
III 93 80.0 25.8
ER/PR/
Her-2 status
ER positive 111 70.8 27.7 0.01
ER negative 50 82.1 24.0
missing 41 75.8 31.3
PR positive 85 70.4 26.4 0.05
PR negative 76 78.6 27.3
missing 41 75.8 31.3
Her-2 positive 36 79.3 21.2 0.11
Her-2 negative 102 70.8 28.8
missing 64 78.1 29.3
Molecular
subtypea
luminal A 75 67.5 29.5 0.09
luminal B 19 78.4 19.8
HER2 16 80.4 24.1
triple negative 26 79.7 25.3
unknown 66 78.1 28.8
aLuminal A, ER-positive and/or PR-positive, Her-2-negative; luminal B,
ER-positive and/or PR-negative, Her-2-postitive; HER2, ER-negative
and PR-negative, Her-2-positive; triple negative, ER-negative, PR-nega-
tive, Her-2-negative.characteristics in patients in the Nashville Breast Health Study, a
population-based case-control study (Zheng et al., 2009). The
specificity of theGTF2IRD1 antibodywas tested by bothwestern
blots and immunohistochemistry staining in multiple tissues,
including breast cancer tissues (Figure S4). We found that higher
GTF2IRD1 expression was significantly associated with higher
tumor grade (p = 0.04). Additionally, estrogen receptor (ER)-
negative (p = 0.01) and progesterone receptor (PR)-negative
(p = 0.05) tumors had higher GTF2IRD1 expression compared
to ER-positive and PR-positive tumors (Table 1). However,
GTF2IRD1 expression was not associated with tumor, node,
and metastases (TNM) stage or tumor size (Tables 1 and S2).
Age at diagnosis, menopausal status, or family history of breast
cancer had no association with GTF2IRD1 protein levels in
the tumor (Table S2). These data demonstrate high levels of
GTF2IRD1 correlate with poor prognostic factors in patients
with breast cancer.
DISCUSSION
In this study, we establish a system to functionally identify
gain-of-function effects on tumorigenesis in the mammary
gland, study the mechanisms through which genes promote
tumor formation, and investigate their clinical relevance. We2094 Cell Reports 15, 2089–2096, June 7, 2016identified four tumor-promoting genes through this approach
that previously had not been associated with cancer. One of
these genes, GTF2IRD1, was further studied for its mecha-
nism and clinical relevance. It significantly accelerates mam-
mary tumor formation in an oncogenic background, and it
correlates with increased tumor grade and poor prognosis in
human patients.
We demonstrate that induction of TbR2 is essential for
GTF2IRD1-driven tumorigenesis and that overexpression of
TbR2 is sufficient to accelerate mammary tumor formation.
GTF2IRD1 or TbR2 each activates TGF-b signaling and promotes
soft agar colony formation in vitro, but they reduce cell prolifera-
tion. Therefore, these genes would not have been revealed as tu-
mor promoters using a classical in vitro screen, highlighting the
importance of using clinically relevant in vivo approaches. Consis-
tent with these paradoxical effects, TbR2 was earlier demon-
strated to be a tumor suppressor gene in early tumor stages, but
also it can behave as a tumor promoter (Massague´, 2012). Loss
of TbR2, for example, promotes metastatic squamous cell carci-
noma and aggressive tumor behavior (Lu et al., 2006; Malkoski
et al., 2012), whereas, in HER2mammary carcinogenesis, a domi-
nant-negative TbR2 mutant delayed tumor onset (Novitskiy et al.,
2014). The other downstream target of GTF2IRD1 is BMPR1b,
which has not been directly linked to tumorigenesis. In our study,
this receptor functions as a mammary tumor suppressor. It will
be instructive in the future todetermine if thesegenes canpromote
tumor formation independentofanyspecificdriver, asseems likely
from the human breast cancer data, or whether they are ErbB2/
HER2 specific. Finally, our in vivo approach can be expanded
easily to a genome-wide gain-of-function screen using a pooled
CRISPR gene activation library, which we expect will reveal addi-
tional gain-of-function genes that can promote breast cancer and
that will be of clinical relevance.EXPERIMENTAL PROCEDURES
Mice
ErbB2 transgenic mice (MMTV-NEU-NDL) were kindly provided by Dr. William
Muller. Male ErbB2 transgenic mice were bred to female FVB mice purchased
from the Jackson Laboratory. No randomization method was used for inbred
mice. All experiments were carried out in accordance with American Associa-
tion for Accreditation of Laboratory Animal Care (AAALAC) guidelines and with
Vanderbilt University Institutional Animal Care and Use Committee approval.
Mammary Stem/Progenitor Cell Isolation and Transplantation
Mammary gland stem/progenitor cells were isolated from 6- to 8-week-old
nulliparous female mice. The third to fifth pairs of mammary glands were
removed and minced. After 45-min digestion at 37C (DMEM/F12, 2 mg/ml
collagenase I [Roche], 5 mg/ml insulin [Sigma], 200 U/ml Nystatin [Sigma],
and 100 U/ml penicillin/streptomycin), epithelial organoids were washed in
5 ml DMEM/F12 containing DNase I and centrifuged at 1,000 rpm for 5 min.
The pellet was resuspended in 5 ml DMEM/F12 with 10% fetal bovine serum
(FBS) followed by 15 s of centrifugation at 1,500 rpm for five times. Organoids
were dissociated in 1 ml fresh 0.05% trypsin/EDTA (Invitrogen) for 12 min
to obtain a single-cell suspension of mammary gland cells. Freshly isolated
mammary gland cells were transduced by lentivirus in a final volume of
200 ml for 1 hr. Cells were cultured for 3 days in mammary epithelial cell
media (DMEM/F12, 5% FBS, 1% insulin-transferrin-selenium [ITS, Gibco],
5 ng/ml epidermal growth factor [EGF, Invitrogen], and 100 U/ml penicillin/
streptomycin) and selected by puromycin (Invitrogen, 2.5 mg/ml) for another
3 days. Then 20,000 mammary cells were transplanted into cleared fats of
3-week-old FVB mice for all experiments except the initial screening. Incisions
were made around the fourth pair of nipples and endogenous mammary
glands were removed. Cells were injected into each cleared fat pad for mam-
mary gland regeneration. All mice were examined each week for palpable tu-
mors. Experiments were terminated once palpable tumors formed in control
mice or the tumor volume reached 2 mm3. Tissues were fixed in formalin
and processed at Vanderbilt Translational Pathology Shared Resource.
For the initial screen, 500,000 cells were injected into one fat pad each of
three to fourmice (23 106 cells total per subpool). Each sub-group contained
about 80 genes and the lentiviral infection efficiency was about 10%. However,
given the heterogeneity of the primarymammary cell population and the lack of
information available on cell of origin for the tumors, we could not reliably esti-
mate actual coverage. If all mammary cells were equally capable of forming
tumors, our library coveragewas2,500; but, if only stem cells acted as the tu-
mor cell of origin, then the coverage was only1.5, assuming 1/2,000 cells is a
stem cell (Huo andMacara, 2014). However, even stem cell frequency can vary
overmore than twoorders ofmagnitude depending on the duration of growth in
culture and the culture conditions (Prater et al., 2014). Since ErbB2+ tumors
have luminal characteristics, we speculated that the cell of origin might be
a luminal progenitor. Sca1-Cd49b+ progenitors constitute about 9% and
Sca1+CD49b+ progenitors about 5% of the total mammary epithelium in
10-week-old virgin mice, and the ratio is similar at 6 weeks (Giraddi et al.,
2015), suggesting a maximum coverage of about 3503. Forty mice in total
were transplanted. The parental vector pLEXwas used as a control in tenmice.
Statistical Analysis
ANOVA was used in the analysis for differences of characteristics and clinico-
pathologic parameters compared to GTF21RD1 expression. The missing indi-
cator method was used for missing covariate information. All the tests were
performed using SAS (version 9.3, SAS Institute). The significance levels
were set at p < 0.05 and based on two-sided probability. For other experiments
a two-tailed paired Student’s t test was used.
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